for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

AstraZeneca plc

AZN.L

Latest Trade

7,006.00GBp

Change

-114.00(-1.60%)

Volume

1,693,854

Today's Range

6,983.00

 - 

7,072.00

52 Week Range

5,871.00

 - 

10,120.00

As of on the London Stock Exchange (LON) ∙ Minimum 15 minute delay

Pricing

Previous Close
7,120.00
Open
7,072.00
Volume
1,693,854
3M AVG Volume
52.07
Today's High
7,072.00
Today's Low
6,983.00
52 Week High
10,120.00
52 Week Low
5,871.00
Shares Out (MIL)
1,312.70
Market Cap (MIL)
93,271.59
Forward P/E
19.95
Dividend (Yield %)
3.03

Next Event

AstraZeneca PLC Virtual Roadshow - Asia Pacific

Latest Developments

更多

Novavax Expects To Start Pediatric Studies For Its Covid-19 Vaccine In Spring

Astrazeneca To Withdraw Imfinzi U.S. Indication For Advanced Bladder Cancer

AstraZeneca Says Enhertu Authorised In UK For Treatment Of HER2 Positive Metastatic Breast Cancer

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About AstraZeneca plc

AstraZeneca PLC is a biopharmaceutical company. It focuses on discovery and development of products, which are then manufactured, marketed and sold. It focuses on three main therapy areas: Oncology, Cardiovascular, Renal & Metabolic (CVRM) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVRM, it is expanding its portfolio into the cardiovascular-renal area with roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). It has approximately 38 projects in Phase I, including 26 new molecular entities (NMEs), and 12 oncology combination projects. It has approximately 43 projects in Phase II, including 25 NMEs; six additional indications for projects that have reached phase II, and 12 oncology combination projects. It has approximately 22 projects in late-stage development, either in Phase III/pivotal Phase II studies or under regulatory review.

Industry

Biotechnology & Drugs

Contact Info

1 Francis Crick Avenue

CB2 0AA

United Kingdom

+44.20.73045000

https://www.astrazeneca.com/Home

Executive Leadership

Leif Johansson

Independent Non-Executive Chairman of the Board

Pascal Soriot

Chief Executive Officer, Executive Director

Marc Dunoyer

Chief Financial Officer, Executive Director

Jeffrey A. Pott

Chief Human Resource Officer, General Counsel

Katarina Ageborg

Executive Vice President - Sustainability, Chief Compliance Officer

Key Stats

2.00 mean rating - 28 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

22.1K

2019

24.4K

2020

26.6K

2021(E)

31.0K
EPS (USD)

2018

3.460

2019

3.500

2020

4.020

2021(E)

5.053
Price To Earnings (TTM)
41.27
Price To Sales (TTM)
4.95
Price To Book (MRQ)
8.44
Price To Cash Flow (TTM)
21.83
Total Debt To Equity (MRQ)
130.46
LT Debt To Equity (MRQ)
115.18
Return on Investment (TTM)
7.13
Return on Equity (TTM)
4.91

Latest News

Latest News

UPDATE 1-AstraZeneca says it will have no vaccine supply shortfall in Q2, EU wary

AstraZeneca will deliver 180 million COVID-19 vaccines to Europe in the second quarter, including 20 million to Italy, the head of its Italian unit was quoted as saying on Thursday, but EU officials remained wary about supply.

UPDATE 1-India's health workers balk at taking homegrown COVID-19 vaccine

* Only 11% of 10.5 million people used Bharat Biotech vaccine

Upbeat German data lifts European shares; Puma, AstraZeneca weigh

European shares rose on Wednesday, supported by stronger-than-expected growth in Germany's economy, although concerns over a possible rise in inflation and lofty equity valuations kept gains in check.

Ireland says has factored in lower Q2 Astrazeneca vaccine supply

The arrival of fewer AstraZeneca COVID-19 vaccines in the European Union during the second quarter has been factored into Irish forecasts that were updated on Tuesday, Prime Minister Micheál Martin said.

AstraZeneca expects U.S. COVID-19 vaccine authorization in April

AstraZeneca Plc expects its COVID-19 vaccine could receive U.S. Emergency Use Authorization at the beginning of April and could immediately deliver 30 million doses of the shot there, a top executive said at a hearing in the U.S. House of Representatives on Tuesday.

CORRECTED-UPDATE 4-More German state workers to get AstraZeneca jab as doses go begging

* Some health workers baulk at AstraZeneca, leaving doses unused

UPDATE 1-AstraZeneca to withdraw Imfinzi U.S. indication for advanced bladder cancer

AstraZeneca will voluntarily withdraw the use of its cancer drug Imfinzi to treat advanced bladder cancer in the United States after it failed to meet post-approval requirements, the Anglo-Swedish drugmaker said on Monday.

AstraZeneca withdraws Imfinzi U.S. indication for advanced bladder cancer

British drugmaker AstraZeneca said on Monday it was voluntarily withdrawing an indication of its cancer drug Imfinzi for treatment of advanced bladder cancer in the United States after it failed to meet post-approval requirements.

EU agreed to pay 870 mln euros for supply of AstraZeneca vaccines by June, contract shows

The European Union agreed to pay about 870 million euros ($1.06 billion) for its supply of 300 million doses of AstraZeneca's COVID-19 vaccine and to receive them by June, the contract published on Friday by Italy's RAI television shows.

AstraZeneca/Oxford vaccine more effective with longer dose gap - study

AstraZeneca and Oxford University's COVID-19 vaccine is more effective when its second dose is given three months after the first, instead of six weeks, a peer-reviewed study published in The Lancet medical journal showed on Friday.

UPDATE 1-S.Korea PM vouches for AstraZeneca vaccine safety ahead of first shipments

South Korea's prime minister assured there were no safety issues with AstraZeneca's coronavirus vaccine on Friday, as the government held final drills ahead of next week's scheduled rollout of the first vaccines.

S.Korea PM vouches for AstraZeneca vaccine safety ahead of first shipments

South Korea's prime minister assured there were no safety issues with AstraZeneca's coronavirus vaccine on Friday, as the government held final drills ahead of next week's scheduled rollout of the first vaccines.

AstraZeneca vaccine faces resistance in Europe after health workers suffer side-effects

* AstraZeneca: vaccine reactions in line with clinical trials

UPDATE 1-Australia's CSL half-year profit jumps 45% on strong blood plasma product demand

Australian biotech CSL Ltd on Thursday reported a 45% rise in half-year profit, boosted by higher demand for its vaccines and blood plasma products.

UPDATE 2-Spain to widen AstraZeneca vaccine use as contagion slows

Spain will administer AstraZeneca's coronavirus vaccine to people aged 45 to 55 in the next phase of its national inoculation plan, the Health Ministry said on Wednesday, as new figures showed the third wave of infection receding further.

Spain to give AstraZeneca COVID vaccine to 45-55 year olds in next phase

Spain will administer AstraZeneca's coronavirus vaccine to people aged 45-55 in the next phase of the national inoculation plan, the Health Ministry said on Wednesday.

EU says AstraZeneca COVID-19 vaccine production capacity in Belgium has sharply increased

European Union industry commissioner Thierry Breton said on Wednesday the COVID-19 vaccine production capacity of a factory in Belgium that produced shots for AstraZeneca had "drastically" increased.

Argentina set to receive first shipment of AstraZeneca vaccine from India Wednesday

Argentina is set to receive 580,000 doses of the Oxford University-AstraZeneca vaccine from India's Serum Institute on Wednesday, a government spokesperson said on Tuesday, bringing the country a step closer to launching a large-scale vaccination program.

UPDATE 2-S.Africa wants to return 1 mln AstraZeneca vaccine doses to Serum Institute-report

South Africa wants to return the one million COVID-19 vaccine doses it has received from Serum Institute of India, The Economic Times reported on Tuesday, a week after the country said it would put on hold use of AstraZeneca's shot in its vaccination program.

Australia medical regulator approves AstraZeneca's COVID-19 vaccine

Australia's medical regulator said on Tuesday it had granted provisional approval for the COVID-19 vaccine developed by AstraZeneca, making it the second vaccine to get regulatory approval in Australia.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up